Is Stem Cell Therapy in Mexico Safe? A Checklist for U.S. Patients

Reviewed for factual and regulatory accuracy using FDA, CDC, COFEPRIS, SEP, CONACEM, ISSCR, and Cochrane sources.

Stem cell therapy in Mexico should not be considered safe or unsafe based on geography alone. Safety depends on the physician, the patient evaluation, the cellular product, the way it is handled, the medical facility, the informed-consent process, and the follow-up plan.

No medical procedure is free of risk, and stem cell therapy is not appropriate for every patient. A responsible clinic should be able to explain what it proposes to use, why it may be considered for your condition, what evidence supports the decision, and what remains uncertain.

Safety factor	Why it matters	What to verify
Physician credentials	Identifies who is responsible for medical decisions	Name, professional license, training, and direct involvement
Patient evaluation	Helps identify contraindications and inappropriate candidates	Medical history, diagnosis, imaging, and medication review
Cellular product	Clarifies what will be administered	Tissue source, donor or patient origin, processing, and documentation
Clinical environment	Helps reduce procedural and infection risks	Facility, safety protocols, responsible staff, and emergency plan
Informed consent	Helps the patient understand risks, limitations, and alternatives	Written information without guaranteed outcomes
Follow-up	Supports continuity after international travel	Written instructions, medical records, and an accessible clinical contact

Why Do U.S. Patients Consider Stem Cell Therapy in Mexico?

Patients from the United States may consider treatment in Mexico because costs and treatment availability can differ. Destinations such as Los Cabos can also allow patients to organize evaluation, treatment-related transportation, lodging, and recovery within one coordinated trip.

Availability does not prove that a treatment is appropriate, effective, or low-risk for a particular patient.

The U.S. Food and Drug Administration states that regenerative medicine therapies are not approved in the United States for orthopedic conditions such as osteoarthritis, tendonitis, disc disease, and knee, hip, back, neck, or shoulder pain. This describes U.S. regulatory status. It does not establish that every treatment offered elsewhere is unsafe, nor does it prove that treatment outside the United States is automatically appropriate.

A 2025 Cochrane systematic review evaluated 25 randomized trials involving 1,341 participants with knee osteoarthritis. It concluded that stem cell injections may slightly improve pain and function compared with placebo, but the evidence was rated low certainty. The reviewers remained uncertain about quality of life, treatment success, structural progression, and safety. The cell source, preparation method, and dose also varied across studies, so these findings should not be generalized to every cellular product or condition.

Some patients investigate regenerative medicine because they are looking for a nonsurgical option that may help manage joint symptoms or support function. Results vary from patient to patient. A medical evaluation is necessary to determine whether a procedure may be appropriate and whether other options should also be considered.

Mexico regulates establishments and activities involving stem cells and regenerative medicine. COFEPRIS states that establishments dedicated to stem cell activities and regenerative medicine require a sanitary license before beginning operations. COFEPRIS also publishes licensing categories and authorization lists related to stem cell and regenerative medicine establishments.

The existence of a regulatory pathway does not establish that every cellular product is effective or that a particular patient should receive it.

A more useful question is: What evidence can this clinic provide that its physician, facility, cellular product, treatment plan, and follow-up process are appropriate for my case?

How to Choose a Stem Cell Clinic in Mexico: A 10-Point Safety Checklist

1. A licensed physician reviews your case

The person answering your first questions may be a patient coordinator, but diagnosis, candidacy, and treatment decisions should involve a qualified physician.

Ask for the physician’s complete name, professional background, role in the procedure, and Mexican professional license number. Mexico’s official Sistema de Cédulas Profesionales allows patients to review professional credentials. When a physician presents as a certified medical specialist, patients may also consult CONACEM’s public certification directory.

Ask:

• Who will review my medical records and decide whether I may be a candidate?
• Who will perform or supervise the procedure?
• Will I meet the physician before making a final decision?
• How can I verify the physician’s credentials?

A coordinator should not diagnose your condition, select your treatment, or guarantee an outcome.

2. The clinic requests medical records and imaging

A clinic should understand what it is being asked to treat before accepting a patient.

Depending on the condition involved, the evaluation may include: medical history, current diagnosis, previous procedures or treatments, medications and allergies, recent imaging, laboratory results, reports from treating physicians, and current symptoms and functional limitations.

Be cautious when a clinic recommends the same treatment to nearly everyone without reviewing the diagnosis, severity of joint damage, or relevant medical risks.

A reasonable preliminary evaluation should help answer:

• What is the working diagnosis and how advanced is the condition?
• What treatments have already been attempted?
• Are there factors that could increase procedural risk?
• Is the patient’s goal medically realistic?

An online consultation may help begin the process, but it may not replace a physical examination when one is medically necessary.

Learn more about Cabo Regenerative Medicine’s stem cell therapy approach.

3. The diagnosis and treatment goal are clearly explained

“Stem cell therapy” is a broad label, not a complete treatment plan.

The clinic should explain the condition being addressed and the intended clinical goal. For an orthopedic patient, that goal might involve symptom management, function, mobility, or another defined objective.

The clinic should not casually promise that damaged cartilage, bone, or other tissue will completely regenerate.

Ask the physician:

• What exactly are you trying to improve, and why is this treatment being considered for my diagnosis?
• What outcome would be medically realistic?
• What evidence supports its use for patients with a similar condition?
• What alternatives should I consider?

A trustworthy explanation includes uncertainty. It should not turn early, limited, or condition-specific evidence into a personal promise.

4. The source of the cells is disclosed

Patients should know what is being administered.

Ask whether the cells or cellular product are obtained from your own body or from a donor. Ask about the tissue source, where it is collected, where it is processed, and which laboratory, tissue establishment, or cell bank is involved.

The clinic should describe the product in language a patient can understand. Labels such as “young cells,” “premium cells,” or “powerful cells” are not substitutes for meaningful documentation.

Useful questions include:

• Are the cells autologous or donor-derived, and what tissue are they obtained from?
• Where and how are they collected and processed?
• What testing or quality controls are performed?
• How is the product traced to the patient and documented in my medical record?

The International Society for Stem Cell Research Guide to Stem Cell Treatments recommends that patients ask about the scientific evidence, regulatory oversight, risks, informed consent, and identity of the treatment being offered.

How can you verify the cellular product instead of relying on a verbal answer?

Ask whether the clinic can provide documentation identifying the tissue source, responsible processing facility, product or batch identifier, applicable quality testing, and traceability information recorded in your medical file. The documentation available will depend on the type of cellular product being used, but the clinic should be able to explain what records exist and which information the patient will receive.

5. The preparation and handling process are documented

The source of the cells is only one part of the safety assessment. Collection, processing, storage, transportation, and administration can also affect risk.

Ask who is responsible for the product at each stage. Depending on the product and procedure, relevant documentation may include: collection information, processing records, storage requirements, transport controls, testing information, product identification, traceability records, and documentation in the patient’s clinical file.

Patients do not need to become laboratory experts. They should, however, expect clear explanations instead of vague assurances.

A clinic should be willing to explain which facility handles the cells, whether the product is prepared onsite or elsewhere, how identity and traceability are maintained, and what quality controls are used.

6. The procedure takes place in an appropriate medical facility

Ask for the exact name and location of the facility where the procedure will occur.

The clinical setting should be appropriate for the proposed intervention and should have trained personnel, infection-prevention procedures, necessary medical equipment, and a plan for responding to unexpected events.

The CDC Yellow Book 2026 chapter on medical tourism notes that medical procedures carry risks regardless of where they are performed. It advises patients and healthcare professionals to consider facility quality, professional credentials, follow-up arrangements, medical-record transfer, and the risks of combining treatment with travel activities.

Ask:

• Where will the procedure be performed and who is the responsible physician?
• What safety and infection-control protocols are followed?
• What happens if an unexpected reaction occurs?
• Is there an established referral or emergency plan?

A polished website, resort setting, or transportation package cannot replace an appropriate medical environment.

Learn more about the clinic.

7. Risks, limitations, and alternatives are discussed

Informed consent should be more than a signature collected immediately before treatment.

The physician should explain: the proposed procedure and its intended goal, known and reasonably foreseeable risks, limitations in the available evidence, the possibility that the expected result may not occur, reasonable alternatives, what happens if the patient decides not to proceed, and how follow-up will be handled.

The FDA has reported risks associated with unapproved or inadequately controlled human cell and tissue products, including infection, contamination, inflammatory or immune reactions, unexpected tissue growth, and failure to produce the anticipated result. These warnings concern products under U.S. jurisdiction, but they illustrate why product identity, handling, and honest risk communication matter.

Patients should have enough time to review the information, ask questions, and consider alternatives before paying or traveling.

8. No guaranteed outcomes are promised

No physician can guarantee that stem cell therapy will eliminate pain, restore cartilage, or prevent a future medical procedure.

Be cautious with statements such as: “100% effective,” “guaranteed regeneration,” “permanent results,” “you will never need surgery,” “this works for every patient,” “there are no risks,” or “you are definitely a candidate” before medical review.

A clinic may explain the proposed treatment goal, available evidence, and its clinical process. It cannot know with certainty how an individual patient will respond.

A trustworthy clinic should be willing to explain what is known, what remains uncertain, and why a treatment may or may not be appropriate for a particular patient.

9. You receive a written follow-up plan

Follow-up should be planned before the patient leaves the United States, not improvised after the procedure.

The CDC recommends coordinating local follow-up care before travel and arranging continuity of care after the patient returns home. It also recommends access to physician licensing information, facility information, and appropriate transfer of medical records.

Before traveling, ask:

• When will the first follow-up take place and who will answer medical questions after I return home?
• Which symptoms require medical attention?
• Will I receive a procedure report identifying the product administered?
• Can information be shared with my physician in the United States?

“Contact us if you need anything” is not as useful as a documented plan with clear responsibilities.

10. Travel logistics are coordinated around medical needs

Medical travel to Mexico for stem cell therapy requires more planning than booking a procedure and a flight.

The trip should be organized around evaluation, treatment, and recovery. The procedure should not be squeezed into a vacation itinerary without considering medical instructions.

The plan may need to address: arrival time, in-person evaluation, transportation, mobility needs, medication management, an accompanying adult, lodging, activity restrictions, recovery time, timing of the return flight, and follow-up after returning home.

Ask the treating physician, rather than a travel salesperson, when you may safely walk longer distances, drive, exercise, swim, consume alcohol, participate in excursions, or board a return flight. The correct instructions depend on the procedure, treatment site, and patient’s overall health.

Learn about medical travel coordination in Los Cabos.

When Should You Pause Before Booking?

Pause and request more information when:

1. No physician has reviewed your records.
2. The cellular product cannot be clearly identified.
3. Risks, limitations, and alternatives have not been explained.
4. Credentials or facility information cannot be verified.
5. Follow-up after returning home is undefined.
6. The clinic guarantees a result.

These concerns do not automatically prove that a clinic is unreliable. They indicate that the patient does not yet have enough verifiable information to make an informed decision.

Red Flags U.S. Patients Should Watch For

Red flag	Why it matters	Better practice
A guaranteed cure	Individual outcomes cannot be guaranteed	Realistic, individualized expectations
The same treatment for everyone	Diagnosis and severity differ	Case-by-case evaluation
No records or imaging requested	Important risks may be missed	Medical review before scheduling
A vague description of the cells	The patient cannot understand what is being administered	Clear source and processing information
Pressure to pay immediately	Limits informed decision-making	Time to review the plan and ask questions
No consent information until arrival	Risks may be disclosed too late	Information provided before travel
No follow-up plan	Creates a gap after returning home	Scheduled follow-up and accessible contact
Tourism emphasized more than medicine	Luxury does not establish clinical quality	Medical planning comes first
“FDA registered” presented as “FDA approved”	Registration and approval are not equivalent	Precise regulatory language
Testimonials used as proof	One experience cannot predict another	Evidence, limitations, and individual evaluation

One red flag does not necessarily prove that a clinic is unreliable. It is a reason to pause, request clarification, and independently verify the answer.

A pattern of vague explanations, exaggerated promises, and payment pressure is more concerning than an isolated wording error.

Not sure which records are needed?

Contact Cabo Regenerative Medicine to learn what medical information is required before a case can be reviewed.

Request information about an initial evaluation.

How Cabo Regenerative Medicine Approaches Patient Safety

At Cabo Regenerative Medicine, the patient process begins with an individual review rather than an automatic treatment recommendation.

The clinic’s approach includes:

• Reviewing the patient’s condition and available medical information
• Determining whether additional evaluation is necessary
• Assessing whether the patient may be a candidate
• Providing medical oversight through Dr. Hugo Armenta
• Discussing treatment goals, limitations, and expectations
• Coordinating treatment-related travel in Los Cabos
• Maintaining communication before and after treatment
• Providing follow-up after the patient returns home

Travel coordination is designed to support the medical plan. It does not replace clinical evaluation, informed consent, or individualized medical instructions.

Patients are encouraged to ask questions, review their options, and understand that a final recommendation can only be made after an appropriate evaluation.

Meet Dr. Hugo Armenta or request a medical evaluation.

Frequently Asked Questions

Is stem cell therapy in Mexico safe for American patients?

Safety cannot be determined by the country alone. Patients should evaluate the physician, facility, cellular product, handling process, candidacy assessment, informed consent, and follow-up plan before deciding.

How can I verify a doctor’s credentials in Mexico?

Ask for the physician’s complete name and professional license number. Mexico has an official professional credential system, and specialty certification can be reviewed through CONACEM when applicable.

Is stem cell therapy legal in Mexico?

Mexico regulates establishments and activities involving stem cells and regenerative medicine. The regulatory status of a specific treatment depends on the facility, cellular product, activities performed, and medical use being proposed. Patients should ask which authorizations apply to each part of the treatment.

Are stem cell treatments for joint pain FDA-approved?

The FDA states that regenerative medicine therapies are not approved in the United States for orthopedic conditions such as osteoarthritis and knee, hip, back, neck, or shoulder pain. FDA approval is a U.S. regulatory status and is separate from Mexican licensing or authorization.

What should I ask about the source of the cells?

Ask whether the cells are obtained from you or a donor, which tissue they come from, where they are collected and processed, what testing is performed, and how the product is traced to your medical record.

Who handles follow-up after I return to the United States?

The clinic should identify a medical contact, provide written instructions, and schedule follow-up before treatment. Patients should also receive records that can be shared with their physician at home when additional care is needed.

Additional answers are available in the clinic’s frequently asked questions.

Find Out Whether You May Be a Candidate

Choosing a clinic should begin with medical information, not a sales package.

Contact Cabo Regenerative Medicine to learn which medical records are required for an initial review and whether a consultation should be scheduled.

Request a medical evaluation

Stem cell therapy is not appropriate for every patient, and outcomes cannot be guaranteed. Results vary from patient to patient. A medical evaluation is necessary to determine whether a treatment may be appropriate for your condition.

---

Medical and Regulatory Sources

1. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021.
2. Centers for Disease Control and Prevention. Medical Tourism. CDC Yellow Book: Health Information for International Travel, 2026 edition. April 23, 2025.
3. Comisión Federal para la Protección contra Riesgos Sanitarios. Establecimientos de Servicios de Salud. July 25, 2025.
4. Comisión Federal para la Protección contra Riesgos Sanitarios. Solicitud de Licencia Sanitaria para Establecimientos de Medicina Regenerativa. Accessed July 31, 2026.
5. International Society for Stem Cell Research. The ISSCR Guide to Stem Cell Treatments. Accessed July 31, 2026.
6. Secretaría de Educación Pública, Dirección General de Profesiones. Sistema de Cédulas Profesionales. Accessed July 31, 2026.
7. Comité Normativo Nacional de Consejos de Especialidades Médicas. Buscador de Médicos Especialistas con Certificación Vigente. Accessed July 31, 2026.
8. Whittle SL, Johnston RV, McDonald S, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. Published April 2, 2025.